Literature DB >> 11747720

Advanced age a risk factor for illness temporally associated with yellow fever vaccination.

M Martin1, L H Weld, T F Tsai, G T Mootrey, R T Chen, M Niu, M S Cetron.   

Abstract

In 1998, the Centers for Disease Control and Prevention was notified of severe illnesses and one death, temporally associated with yellow fever (YF) vaccination, in two elderly U.S. residents. Because the cases were unusual and adverse events following YF vaccination had not been studied, we estimated age-related reporting rates for systemic illness following YF vaccination. We found that the rate of reported adverse events among elderly vaccinees was higher than among vaccinees 25 to 44 years of age. We also found two additional deaths among elderly YF vaccinees. These data signal a potential problem but are not sufficient to reliably estimate incidence rates or to understand potential underlying mechanisms; therefore, enhanced surveillance is needed. YF remains an important cause of severe illness and death, and travel to disease-endemic regions is increasing. For elderly travelers, the risk for severe illness and death due to YF infection should be balanced against the risk for systemic illness due to YF vaccine.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11747720      PMCID: PMC2631902          DOI: 10.3201/eid0706.010605

Source DB:  PubMed          Journal:  Emerg Infect Dis        ISSN: 1080-6040            Impact factor:   6.883


  25 in total

1.  [Encephalitis in children in Costa Rica and Honduras after Dakar yellow fever vaccination].

Authors:  C M EKLUND
Journal:  Bol Oficina Sanit Panam       Date:  1953-11

2.  Fatal yellow fever in a traveler returning from Venezuela, 1999.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2000-04-14       Impact factor: 17.586

3.  Jungle yellow fever in the central Amazon.

Authors:  M L Barros; G Boecken
Journal:  Lancet       Date:  1996-10-05       Impact factor: 79.321

4.  Hepatitis and death following vaccination with 17D-204 yellow fever vaccine.

Authors:  R C Chan; D J Penney; D Little; I W Carter; J A Roberts; W D Rawlinson
Journal:  Lancet       Date:  2001-07-14       Impact factor: 79.321

5.  Persistence of neutralizing antibody 30-35 years after immunization with 17D yellow fever vaccine.

Authors:  J D Poland; C H Calisher; T P Monath; W G Downs; K Murphy
Journal:  Bull World Health Organ       Date:  1981       Impact factor: 9.408

Review 6.  Epidemiology of poliomyelitis in the United States one decade after the last reported case of indigenous wild virus-associated disease.

Authors:  P M Strebel; R W Sutter; S L Cochi; R J Biellik; E W Brink; O M Kew; M A Pallansch; W A Orenstein; A R Hinman
Journal:  Clin Infect Dis       Date:  1992-02       Impact factor: 9.079

7.  Urbanisation of yellow fever in Santa Cruz, Bolivia.

Authors:  P Van der Stuyft; A Gianella; M Pirard; J Cespedes; J Lora; C Peredo; J L Pelegrino; V Vorndam; M Boelaert
Journal:  Lancet       Date:  1999-05-08       Impact factor: 79.321

8.  Fever, jaundice, and multiple organ system failure associated with 17D-derived yellow fever vaccination, 1996-2001.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2001-08-03       Impact factor: 17.586

9.  West Nile encephalitis epidemic in southeastern Romania.

Authors:  T F Tsai; F Popovici; C Cernescu; G L Campbell; N I Nedelcu
Journal:  Lancet       Date:  1998-09-05       Impact factor: 79.321

10.  THE USE OF YELLOW FEVER VIRUS MODIFIED BY IN VITRO CULTIVATION FOR HUMAN IMMUNIZATION.

Authors:  M Theiler; H H Smith
Journal:  J Exp Med       Date:  1937-05-31       Impact factor: 14.307

View more
  26 in total

1.  Yellow fever vaccine.

Authors:  Philip P Mortimer
Journal:  BMJ       Date:  2002-02-23

2.  Yellow Fever Immunizations: Indications and Risks.

Authors:  Mary E. Wilson; Lin H. Chen; Elizabeth D. Barnett
Journal:  Curr Infect Dis Rep       Date:  2004-02       Impact factor: 3.725

3.  A case of yellow fever vaccine-associated viscerotropic disease in Ecuador.

Authors:  Richard W Douce; Diana Freire; Betzabe Tello; Gavino A Vásquez
Journal:  Am J Trop Med Hyg       Date:  2010-04       Impact factor: 2.345

Review 4.  The safety of yellow fever vaccine 17D or 17DD in children, pregnant women, HIV+ individuals, and older persons: systematic review.

Authors:  Roger E Thomas; Diane L Lorenzetti; Wendy Spragins; Dave Jackson; Tyler Williamson
Journal:  Am J Trop Med Hyg       Date:  2012-02       Impact factor: 2.345

Review 5.  Adversomics: a new paradigm for vaccine safety and design.

Authors:  Jennifer A Whitaker; Inna G Ovsyannikova; Gregory A Poland
Journal:  Expert Rev Vaccines       Date:  2015-05-02       Impact factor: 5.217

6.  A small animal peripheral challenge model of yellow fever using interferon-receptor deficient mice and the 17D-204 vaccine strain.

Authors:  Brett A Thibodeaux; Nina C Garbino; Nathan M Liss; Joseph Piper; Carol D Blair; John T Roehrig
Journal:  Vaccine       Date:  2012-03-13       Impact factor: 3.641

7.  A humanized IgG but not IgM antibody is effective in prophylaxis and therapy of yellow fever infection in an AG129/17D-204 peripheral challenge mouse model.

Authors:  Brett A Thibodeaux; Nina C Garbino; Nathan M Liss; Joseph Piper; Jacob J Schlesinger; Carol D Blair; John T Roehrig
Journal:  Antiviral Res       Date:  2012-02-15       Impact factor: 5.970

8.  A single amino acid substitution in the envelope protein of chimeric yellow fever-dengue 1 vaccine virus reduces neurovirulence for suckling mice and viremia/viscerotropism for monkeys.

Authors:  F Guirakhoo; Z Zhang; G Myers; B W Johnson; K Pugachev; R Nichols; N Brown; I Levenbook; K Draper; S Cyrek; J Lang; C Fournier; B Barrere; S Delagrave; T P Monath
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

9.  Safety and efficacy of chimeric yellow Fever-dengue virus tetravalent vaccine formulations in nonhuman primates.

Authors:  F Guirakhoo; K Pugachev; Z Zhang; G Myers; I Levenbook; K Draper; J Lang; S Ocran; F Mitchell; M Parsons; N Brown; S Brandler; C Fournier; B Barrere; F Rizvi; A Travassos; R Nichols; D Trent; T Monath
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

10.  A randomized, double-blind, controlled trial of the 17D yellow fever virus vaccine given in combination with immune globulin or placebo: comparative viremia and immunogenicity.

Authors:  Srilatha Edupuganti; Rachel B Eidex; Harry Keyserling; Rama S Akondy; Robert Lanciotti; Walter Orenstein; Carlos del Rio; Yi Pan; Troy Querec; Harvey Lipman; Alan Barrett; Rafi Ahmed; Dirk Teuwen; Martin Cetron; Mark J Mulligan
Journal:  Am J Trop Med Hyg       Date:  2012-12-03       Impact factor: 2.345

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.